Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, after the company posted better-than-expected fourth-quarter earnings, boosted by strong demand for a new formulation of its blockbuster eye drug Eylea.
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, after the company posted better-than-expected fourth-quarter earnings, boosted by strong demand for a new formulation of its blockbuster eye drug Eylea.
